Home medicines
 

Keywords :   


Tag: medicines

European Medicines Agencys CHMP Recommends Mercks KEYTRUDA (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor...

2016-12-16 13:26:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Opinion Based on Findings from KEYNOTE-024 Trial, Which Showed Superior Overall Survival and Progression Free Survival with KEYTRUDA Compared to Chemotherapy First Anti-PD-1 Therapy to Receive a CHMP Positive Opinion for Previously Untreated Patients with Metastatic NSCLC KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tu Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more

Tags: or with high positive

 

Merck Launches Biosimilars Clarified, a New Online Educational Resource about Biosimilar Medicines for Patients and the Healthcare Community

2016-10-14 14:30:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of Biosimilars Clarified (www.merckclarifiesbiosimilars.com), a new educational website for patients, caregivers and the healthcare community that is designed to provide clear, concise and straightforward information about biosimilar medicines. Language: English Contact: MerckRobert Consalvo, 908-236-1127 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the online community resource

 
 

Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association

2016-05-12 14:30:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Additional Analyses from the TECOS Cardiovascular Safety Trial of JANUVIA (sitagliptin) Also to Be Presented KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will present data from clinical trials of its investigational diabetes pipeline, JANUVIA (sitagliptin), and new real-world research in more than 20 scientific data presentations at the 76th Scientific Sessions of the American Diabetes Association (ADA) being held in New Orleans, June 10-14, 2016. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Kristen Drake, 908-236-4223orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the data present american

 

05.05.16 -- twoXAR Joins Stanford University In Hunt For Medicines Targeting Rare Diseases

2016-05-04 03:07:36| drugdiscoveryonline Home Page

05/05/16 Drug Discovery Online Newsletter

Tags: university rare diseases hunt

 

twoXAR Joins Stanford University In Hunt For Medicines Targeting Rare Diseases

2016-05-03 03:04:31| drugdiscoveryonline News Articles

twoXAR, Inc., a company dedicated to improving health through computation, recently announced a collaboration with Joyce Teng, MD, PhD, of the Department of Dermatology at Stanford University to support research focused on the identification of drug candidates targeting rare disorders such as lymphatic malformation and epidermolysis bullosa simplex (EBS)

Tags: university rare diseases hunt

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] next »